Tristan Imbert's Co-Option as Independent Director
EUROAPI has made significant strides by appointing Tristan Imbert as an Independent Director following the recent resignation of Rodolfo Savitzky. This transition is expected to further enhance EUROAPI's leadership as it prepares for a shareholder vote. Imbert's expertise positions him as a key figure in steering the company’s future direction.
The New Role and Responsibilities
Effective January 1, 2026, Tristan Imbert will take up the role of Chair of the Audit Committee, bringing with him a wealth of experience. Imbert's career has spanned both finance and pharmaceuticals, making him a well-rounded asset to EUROAPI. His role will involve overseeing financial reporting and ensuring compliance with best practices, which are critical in maintaining the trust of stakeholders.
Tristan Imbert's Professional Journey
Imbert began his professional journey in research and development with Sanofi Aventis, laying a strong foundation in the pharmaceutical sector. His career advanced as he transitioned to the Boston Consulting Group, where he provided consulting services to pharmaceutical clients across major cities. His tenure at Novartis solidified his financial acumen, ultimately leading him to the role of Chief Financial Officer at Novartis Gene Therapies. Most recently, as CFO of Cimeio Therapeutics, he prepared the company for its potential IPO, showcasing his strategic foresight and financial expertise.
Welcome Message from the Chairman
EUROAPI’s Chairman, Emmanuel Blin, expressed his excitement regarding Imbert’s appointment. He noted that Imbert's vast experience and knowledge in finance, research and development, and strategic planning would significantly benefit the board's decision-making process. Blin also took a moment to thank Rodolfo Savitzky for his contributions during his tenure, highlighting the importance of strong leadership in guiding EUROAPI towards its strategic goals.
Financial Agenda Ahead
Looking ahead, EUROAPI has outlined its financial agenda for upcoming months, with key dates that shareholders and stakeholders should mark in their calendars. The company is set to release its FY 2025 results on March 3, 2026, and hold the 2026 Annual General Meeting on May 27, 2026. Additionally, the H1 2026 results will be announced on July 28, 2026. These milestones are crucial for maintaining transparency and allowing for effective stakeholder engagement.
About EUROAPI
EUROAPI is dedicated to reinventing active ingredient solutions to fulfill the evolving demands of customers and patients. Renowned as a leader in the production of active pharmaceutical ingredients, EUROAPI boasts a portfolio of nearly 200 products, encompassing a wide range of technologies and innovative molecules developed through its Contract Development and Manufacturing Organization (CDMO) initiatives.
Commitment to Health and Well-being
With a passionate workforce of approximately 3,270 individuals, EUROAPI strives daily to make a positive impact in healthcare by ensuring access to vital therapies. The company has established strong research and development capabilities, supported by five manufacturing sites in Europe. Through these efforts, EUROAPI guarantees the highest quality in API manufacturing, supplying healthcare institutions in over 80 countries.
Contact Information for Inquiries
If you have inquiries related to media or investor relations, you can reach out directly to our contacts at EUROAPI. Laurence Bollack is available for media inquiries, and Sophie Palliez-Capian along with Léa Massonneau cater to investor relations. Each is prepared to provide support and further information necessary for understanding the company's strategic initiatives and investor opportunities.
Frequently Asked Questions
What is the significance of Tristan Imbert's appointment?
Tristan Imbert's appointment as Independent Director brings valuable financial insight and pharmaceutical expertise, enhancing EUROAPI's leadership.
When does Tristan Imbert officially start his role?
Imbert will officially take over his role as Chair of the Audit Committee on January 1, 2026.
What previous positions has Tristan Imbert held?
Imbert has held significant roles at Sanofi Aventis, Novartis, and Cimeio Therapeutics, showcasing extensive experience in finance and strategy.
What events are coming up for EUROAPI?
EUROAPI will release its FY 2025 results on March 3, 2026, followed by its AGM on May 27, 2026.
How does EUROAPI ensure quality in its products?
EUROAPI employs strong R&D capabilities and advanced manufacturing practices to produce high-quality active pharmaceutical ingredients.
